Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine
SARASOTA, Fla., May 17, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders, today announced that the company will host a webinar panel on Neurotrauma Medicine Monday, May 20, 2024, at 12:00 PM ET.
- SARASOTA, Fla., May 17, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders, today announced that the company will host a webinar panel on Neurotrauma Medicine Monday, May 20, 2024, at 12:00 PM ET.
- The discussion will address the unmet medical need in Traumatic Brain Injury (TBI), commonly known as concussion, explore common causes, and examine its association with other long-term neurological disorders.
- Additionally, the company will present its lead drug candidate, ONP-002, an innovative neurosteroid designed to treat mild TBI and discuss its outcomes from preclinical and Phase I trials, as well as details of an upcoming Phase II clinical trial to be conducted in acute and emergency departments.
- Details for the webinar are as follows:
James P. Kelly, MA, MD, FAAN, FANA, Emeritus Professor of Neurology and PM&R, University of Colorado School of Medicine
Frank Peacock, IV, MD, FACEP, FACC, FESC, Vice Chair for Emergency Medicine Research, Baylor College of Medicine